

ASX Announcement

17 March 2026

Results of Entitlement Offer

Sydney, Australia – 17 March 2026: OncoSil Medical Limited (ASX: OSL) (**OncoSil** or the **Company**) is pleased to provide the results of the Company’s non-renounceable entitlement offer as announced to ASX on 3 February 2026 (**Entitlement Offer**). The Entitlement Offer raised approximately \$2 million and, together with the underwritten amount, was fully subscribed.

The Entitlement Offer was supported by approximately 6% of eligible OncoSil shareholders, the balance of which was allocated to the underwriter, Bell Potter Securities Limited (**Underwriter**).

The proceeds from the Entitlement Offer and the Placement (as announced on 3 February 2026) will be used to complete clinical trials and manufacturing facility, sales and marketing investment, market access investment and general working capital requirements.

Entitlement Offer

The Entitlement Offer comprised of a non-renounceable entitlement offer of 1 New Share for every 6.4 Shares at an Issue Price of \$0.68 (68 cents) per New Share plus 1 New Option for every 1 New Share issued to raise total gross proceeds of approximately \$2 million.

Further information pertaining to the Entitlement Offer is available in the Prospectus lodged with ASIC and ASX on 3 February 2026 made available on the ASX platform.

The Company received valid applications under the Entitlement Offer for a total of 2,040,217 New Shares at the issue price of \$0.68 per New Share. Eligible Shareholders were also offered the opportunity to apply for additional New Shares in excess of their Entitlement at the issue price of \$0.68 under the Top-Up Facility.

Valid applications from Eligible Shareholders related to the Top-Up Facility were made for 844,394 New Shares and are included in the total valid applications for 2,040,217 New Shares representing total proceeds of approximately \$1.4 million.

The remaining 911,701 New Shares will be issued to the Underwriter as described in the Prospectus. The results of the Entitlement Offer are summarised in the table below.

	Number of New Shares	Number of New Options	Gross Proceeds
Total Applications (including Additional Securities under the Top-Up Facility)	2,040,217	2,040,217	\$1,387,347.56

Shortfall (to be placed to the Underwriter)	911,701	911,701	\$619,956.68
Total number of securities offered under the Entitlement Offer	2,951,918	2,951,918	\$2,007,304.24

The New Shares and New Options will be issued on Tuesday, 17 March 2026 and the Company will lodge an Appendix 2A in respect of the New Shares and New Options.

New Shares issued under the Entitlement Offer will each rank equally with ordinary shares already on issue.

The New Options have an exercise price of \$0.90 and an expiry date of 30 June 2027. OncoSil has sought quotation of the New Options issued under the Entitlement Offer on the ASX.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338</p>
--	---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>